Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Changeyoubet

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Jun 29, 2021 1:00pm

147 Views

Post# 33466552

RE:RE:RE:Changeyoubet

Interesting perspective Mugs, but I think this is where everyone is frustrated. All we heard was P3 delay to Q1 2022. If there are strategic reasons then we should be provided with some transparency. I've emailed Dan ---- haven't heard back (not sure I will), but it's frustrating that we have to email him to get these insights.

MrMugsy wrote:

GameChangerBet wrote: For someone who put me on ignore you sure do mention me a lot.

RE:Bye

YukonJezza wrote:
you are my first stockhouse Ignore

I'm honoured.

Perhaps provide something of substance that we can all share and discuss.

YukonJezza wrote:
changeyouBet, you must be angry , Or your conversations with Dan did not happen and you BS'ed us all.

Well said Gamechanger.

Here's a thought to consider ...

We know why they're working with academia and it seems it's that kind of work that is getting passed along to CRO for further development. Using outside resources because we're too small.

We know why we're looking to update old patents - all about value in negotiations.

What we don't know is ... why are we doing single-dose IND-opening studies and if AME depends on that study before the AME can begin. Why would this matter ?

If I'm looking to buy OTENA and run with that product through Phase 3, maybe I'm requesting these things to be done in advance of a hand-off. I want a better target for pass/fail so that I have more confidence in a speedier P3 ... before I buy this drug. If that were true - it would be easier to understand why Single Dose and AME are getting in the way. It would also be an area that ATE couldn't get into any detailed explanations if negotiations are in a confidential period.

Just something to think about.

Hopefully we can discuss here and the haters can play on the Island of Ignore. : )